AT-12 PHASE 1/2 STUDY OF TH-302, INVESTIGATIONAL HYPOXIA-ACTIVATED PRODRUG, AND BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

BACKGROUND: Hypoxia is implicated in the pathogenesis of glioblastoma multiforme (GBM), and greater hypoxic burden is associated with poorer outcomes in GBM. Treatment with bevacizumab (BEV) may increase intratumoral hypoxia. An ongoing phase 1/2 study (NCT01403610) investigates safety and activity...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Brenner, Andrew, Floyd, John, Eng, Clarence, Kroll, Stew, Fichtel, Lisa, Gruslova, Aleksandra, Lodi, Alessia, Tiziani, Stefano
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2014
Предметы:
Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217789/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.12
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы